{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7"},{"groupId":"OG001","value":"28.4"}]}],"title":"72 hours - Normal [N=107,109]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4"},{"groupId":"OG001","value":"45.9"}]}],"title":"72 hours - Mildly restricted [N=107,109]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1"},{"groupId":"OG001","value":"20.2"}]}],"title":"72 hours - Moderately restricted [N=107,109]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"5.5"}]}],"title":"72 hours - Severely restricted [N=107,109]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"72 hours - Immobilized [N=107,109]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1"},{"groupId":"OG001","value":"97.2"}]}],"title":"24 weeks - Normal [N=79, 71]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1"},{"groupId":"OG001","value":"2.8"}]}],"title":"24 weeks - Mildly restricted [N=79, 71]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0"}]}],"title":"24 weeks - Moderately restricted [N=79, 71]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"0.0"}]}],"title":"24 weeks - Severely restricted [N=79, 71]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"24 weeks - Immobilized [N=79, 71]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"The study physician assessed the range of motion of the most affected joint for range of motion on a 5-point Likert scale: Normal, mildly restricted, moderately restricted, severely restricted, immobilized. The percentage of participants in each category is reported.","groups":[{"description":"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. In the first extension study participants completing the 12 week core study could continue to be treated on demand with the same treatment for another 12 weeks for any new gout flare.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Participants received 1 intramuscular injection of triamcinolone acetonide 40 mg and 1 sc injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.\n\nIn the first extension study participants completing the 12 week core study could continue to be treated on demand with the same treatment for another 12 weeks for any new gout flare.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug. 'N' in each category indicates participants with observations available at the specified time point.","reportingStatus":"POSTED","timeFrame":"72 hours post-dose and 24 weeks post-dose","title":"Physician's Assessment of Range of Motion of the Most Affected Joint","type":"SECONDARY","unitOfMeasure":"percentage of participants"}